Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases.
Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
Entrada Therapeutics is a rapidly growing biopharmaceutical company that can be classified as a scale-up. The company has shown significant progress in expanding its pipeline of intracellular therapeutics and establishing a strong presence in the industry. With a focus on treating devastating diseases, Entrada Therapeutics is in a phase of aggressive growth and development. The company's dedicated focus on intracellular therapeutics sets it apart in the healthcare sector, positioning it for further expansion and success in the future.
Entrada Therapeutics has achieved several key milestones that highlight its growth and success. The company's pipeline expansion, recent data supporting its Duchenne franchise, and the promotion of key personnel like Natarajan Sethuraman to President of Research and Development showcase significant achievements. Entrada Therapeutics' commitment to diversity and advocacy is evident through its DREAMS Grant Program, demonstrating a holistic approach to innovation and social responsibility.
Entrada Therapeutics has been involved in impactful case studies and significant projects within the field of intracellular therapeutics. The company's innovative EEV™ Platform has enabled it to target disease-causing factors within cells that were previously inaccessible. By developing potential treatments for a range of devastating diseases, Entrada Therapeutics is ushering in a new era of therapeutic possibilities. The company's commitment to patient-centric care and scientific excellence is evident in the positive outcomes of its case studies, which have the potential to transform patients' lives and redefine treatment paradigms.
-
Active
Health Care/Life Sciences
One Design Center Place Boston Massachusetts 02210 United States...
United States
159
Gina Chapman (Director)
Peter S. Kim (Director)
Nathan J. Dowden (President & Chief Operating Officer)
Kory James Wentworth (Chief Financial Officer & Treasurer)
129.01 M
$16.99
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDCAiDOOS Information Wiki provides comprehensive information about products, companies, and individuals.
-
Health Care/Life Sciences
One Design Center Place Boston Massachusetts 02210 United States...
United States
159+
129.01 M
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases.
Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDC